middle.news
How Argent BioPharma’s NanoBodies Could Transform Septic Shock Treatment
10:18am on Wednesday 25th of February, 2026 AEDT
•
Biotechnology
Read Story
How Argent BioPharma’s NanoBodies Could Transform Septic Shock Treatment
10:18am on Wednesday 25th of February, 2026 AEDT
Key Points
Provisional patent filed with USPTO for NanoBodies platform
Targets upstream vascular and peptide signalling in septic shock
Complements existing cytokine-modulating therapies
Preclinical proof-of-concept studies planned using CLP septic shock model
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ARGENT BIOPHARMA (ASX:RGT)
OPEN ARTICLE